75 results about "Vaccine Potency" patented technology

T cell immune responses are enhanced by presentation of antigen to CD8⁺ T cells using a chimeric nucleic acid immunogen or vaccine that links DNA encoding an antigen with DNA encoding a polypeptide that targets or translocates the antigenic polypeptide to which it is fused (immunogenicity-potentiating polypeptides or “IPP”). By inhibiting apoptosis in the vicinity of a T cell responses to such a nucleic acid immunogen, even more potent immune responses are attained. The present strategy prolongs the survival of DNA-transduced cells, including dendritic cells (DCs), thereby enhancing the priming of antigen-specific T cells and increase potency. Co-delivery of DNA encoding an inhibitor of apoptosis, including (a) BCL-xL, (b) BCL-2, (c) XIAP, (d) dominant negative caspase-9, or (e) dominant negative caspase-8, or (f) serine protease inhibitor 6 (SPI-6) which inhibits granzyme B, with DNA encoding an antigen, prolongs the survival of transduced DCs and results in significant enhancement of antigenspecific T cell immune responses that provide potent antitumor effects. Thus, co-administration of a DNA vaccine encoding antigen linked to an IPP along with one or more DNA constructs encoding an anti-apoptotic protein provides a novel way to enhance vaccine potency.

A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Disclosed is a method for increasing vaccine potency whereby a subject's immune system is first primed with an Ii-Key hybrid peptide construct before the subject subsequently receives a vaccine for a pathogen of interest. The vaccine may be comprised of a protein or portion thereof that is encoded by the genome of the pathogen. The vaccine may also be a DNA vaccine comprised of DNA encoding a protein of the pathogen. The Ii-Key hybrid peptide construct includes the LRMK residues of Ii-Key protein and an MHC Class II epitope of the protein or portion thereof which is used in the vaccine. The Ii-Key construct may be administered in the form of a nucleic acid construct encoding the Ii-Key hybrid peptide. Priming with Ii-Key peptides enhances the immunogenicity of rHA protein and HA and HIV DNA vaccines. Methods are described relating to the use of Ii-Key hybrid constructs in vaccine protocols wherein the pathogen is HIV or Influenza A, including H5N1. Methods and compositions are described wherein the MHC Class II epitope of the Ii-Key hybrid is hemagglutinin encoded by Influenza A or the Gag protein encoded by HIV.

The present invention is directed to a vaccine adjuvant which improves the vaccine potency. More specifically, the present invention is directed to the use of a γδT lymphocyte activator as vaccine adjuvant to promote and enhance antigen specific immunological responses, as well as a vaccine composition comprising a γδT lymphocyte activator.

The present invention is related to methods of assaying potency of a vaccine composition, wherein the potency is a pre-defined minimum level of potential biological activity for the vaccine composition. The method includes providing a vaccine composition and delivering same to an antigen presenting cell, wherein the vaccine composition is processed into peptides and the peptides are presented by MHC complexes on the cell surface. An agent, such as a T cell receptor mimic, that is reactive against a specific peptide/MHC complex is provided and reacted with the vaccine-treated antigen presenting cell, whereby the agent binds to the cell surface of the vaccine-treated antigen presenting cell if the specific peptide/MHC complex recognized by the agent is present on the cell surface. A density of the specific peptide/MHC complex on the surface of the vaccine-treated antigen presenting cell is measured by agent binding. The potency of the vaccine is then determined based upon the measured density of specific peptide/MHC complex present on the surface of the vaccine-treated antigen presenting cell.

The invention belongs to the technical field of new biological veterinary medicaments, and in particular relates to a method for testing the efficacy of a swine fever live vaccine. The efficacy of the live vaccine is evaluated by detecting the virus content of the live vaccine through indirect immunofluorescence (IFA). The method for testing the efficacy of the swine fever live vaccine has the advantages of short test time, simple operation, low cost, accurate obtained result, high repeatability, excellent application value and wide market prospects.

The invention provides an oil-in-water vaccine adjuvant and a preparation method thereof. According to the technical scheme, category and composition of surfactant are optimized; the stable oil-in-water adjuvant is prepared by virtue of a one-step process, so that autologous cellular and humoral immunity stimulation capacities of a vaccine are enhanced; and especially, the vaccine adjuvant also simultaneously comprises other water-based adjuvant ingredients which are effective on enhancing efficacy of the vaccine, so that attacking protection efficacy of the inactivated vaccine is further improved, and technical problems of an existing oil-in-water vaccine which is low in immunological activity and short in immunity persistence are solved. The preparation method of the nano vaccine adjuvant provided by the invention is simple in process and low in cost, and the obtained vaccine adjuvant is stable in dosage form. The prepared oil-in-water nano emulsion (the vaccine adjuvant) is long in stable period, easy for preservation, good in immunization effect, long in protection term, easy for injection and quite low in side reactions.

A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficient animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of Nerve Growth Factor (NGF) is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine.

The methods and compositions of the present invention are directed to enhancing an immune response and increasing vaccine efficacy through the simultaneous or sequential targeting of specific immune system components. More particularly, specific immune components, such as macrophages, dendritic cells, B cells and T cells, are individually activated by component-specific immunostimulating agents. One such component-specific immunostimulating agent is an antigen-specific, species-specific monoclonal antibody. The invention is also directed to a method for the in vitro production of the antigen-specific, species-specific monoclonal antibodies which relies upon the in vitro conversion of blood-borne immune cells, such as macrophages and lymphocytes. Vaccine efficacy is enhanced by the administration of compositions containing component-specific immunostimulating agents and other elements, such as antigens or carrier particles, such as colloidal methods, such as gold.

A method for induction of endogenous heat shock protein in tumor cells using a simple heat shock treatment which provides a simple and inexpensive method for augmenting antitumor vaccine potency. The method comprises administering to a mammal tumor cells which have been subject to a heat shock condition sufficient to cause induction of endogenous heat shock protein therein. Also disclosed is a composition for enhancing tumor cell immunogenicity comprising a therapeutically effective amount of attenuated tumor cells which have been subject to a heat shock condition.

The invention relates to a recombinant epsilon toxin and alpha toxin fusion protein vaccine of non-toxic clostridium perfringens and a production method of the vaccine. According to an ETX mutant of non-toxic clostridium perfringens and C end fusion protein rETXm3CPAC of CPA, the non-toxic ETX mutant ETXm3 is in serial connection with a C end (CPAC) of CPA, soluble expression is achieved in escherichia coli BL21(DE3), the spatial conformation of natural toxin protein can be reserved to the highest extent, and accordingly the immunogenicity of escherichia coli can be maintained; the influence of a complex technology of inclusion body denaturation and renaturation on immunogenicity of the antigen protein is also avoided, the time of preparing the vaccine is shortened, and the production costis reduced. The C end of rETXm3CPAC contains six histidine (6*His) labels, and convenience is provided for protein purification; the obtained toxin fusion protein is completely free of toxicity in amouse body and has good safety, immunogenicity and immune protection performance in a rabbit model. The vaccine also has the advantages that the preparation technology is good, the efficacy of the vaccine is excellent, and A-type and D-type clostridium perfringens diseases are prevented at the same time.

The present invention relates to the treatment and prevention of cancer. The present invention relates to vaccines comprising solubilized components of cancer cells or cancer-associated cells. Moreover, the present invention also relates to methods of producing vaccines from biological samples comprising cancer cells or cancer-associated cells and using said vaccines for the treatment or prevention of cancer in subjects. The present invention also relates to methods of producing vaccines, in particular, autologous vaccines. The present invention also relates to therapeutic uses of mesenchymal stem cells and to methods of treatment and or prevention that comprise administering mesenchymal stem cells to a subject. The present invention also relates to methods of enhancing the efficacy of vaccines and methods for the treatment and prevention of cancer, and to compositions and kits suitable for use in the methods.

The invention provides a helicobacter pylori mutant strain capable of stimulating immune response and a construction method and application of the helicobacter pylori mutant strain, and belongs to thetechnical field of bioengineering. The mutant strain provided by the invention does not contain a gene futB for encoding glycosyltransferase in an O antigen synthesis process, meanwhile, a lipid A structure is modified, related synthesis genes lpxE and lpxF are knocked out, and the preservation number of the strain is CCTCC NO: M 2020028. The helicobacter pylori outer membrane vesicle vaccine canefficiently stimulate a host to generate immune response and secrete the outer membrane vesicle, so that the helicobacter pylori outer membrane vesicle has the characteristic of high vaccine efficacy. Meanwhile, the method can effectively enable helicobacter pylori lipid A to be recognized by TLR4 again, enables lipid A to have adjuvant activity, and can better serve antigen presentation. The method can be used for constructing novel helicobacter pylori antigen presenting plasmids, antigen protein is presented to periplasmids of bacteria or exposed to the surface of an outer membrane of the bacteria through different strategies, and therefore the efficiency of immunoreaction generated by host recognition of a target antigen is improved.

The invention discloses a therapeutic HPV vaccine based on a chimpanzee adenovirus vector as well as a preparation method and application of the therapeutic HPV vaccine. The therapeutic HPV vaccine isan immunogenic HPV recombinant adenovirus vaccine obtained by packaging and processing HPV virus vaccine vector plasmids, and the HPV virus vaccine vector is a replication-defective chimpanzee adenovirus vector. The HPV therapeutic vaccine is constructed by using the replication-defective chimpanzee adenovirus vector, the influence of the pre-stored immunity of a human adenovirus vector in a human body on the vaccine efficacy is overcome, and a vaccine product which is simple to prepare, low in cost, good in safety and free of adjuvants is expected to be obtained. The therapeutic HPV vaccinehas good immunogenicity and anti-tumor efficacy, can induce high-level antigen-specific T cell reaction and anti-tumor efficacy in a mouse body through single muscle immunization, and is expected to show good humoral and cellular immunotherapy effect can be embodied in human clinical tests.

A method of detecting the presence of a functionally inhibitory immunointeractive molecule in a biological sample. Preferably, the immunointeractive molecule is directed to a pathogen derived antigen and, more particularly, a parasite derived antigen and, even more particularly, a Plasmodium drived antigen. The method of the present invention facilitates detection of the presence of functionally inhibitory immunointeractive molecules, both in vitro and in vivo, and is useful for qualitatively and/or quantitatively assessing the immune status of individuals who have been previously infected with a parasite, predicting the immune status of individuals vaccinated with an antigen based vaccine, determining the relative contribution of a specific immunoreactivity of antibody to the total inhibitory antibody elicited by combination vaccines which include two or more antigens, assessing vaccines to determine the efficacy of different forms of an antigen, determining vaccine potency, assessing the protective potential of certain immunoreactivities of antibodies and determining the importance of parasite inhibitory antibodies.

The present disclosure describes compositions containing cyclodextrin and methods of using cyclodextrins to stimulate or enhance the immune system and response in fish. Methods of enhancing the efficacy of a fish vaccine by administering cyclodextrin to the fish are also described.

The invention discloses a veterinary bovine ephemeral fever inactivated vaccine and a large-scale production method thereof, and belongs to the technical field of vaccine production. The method provided by the invention comprises the steps of performing cell culture by utilizing a suspension culture process, performing virus suspension culture, performing virus antigen solution clarification, performing concentration and purification, performing inactivation and performing emulsification vaccine preparation, and the method can realize mass proliferation of the bovine ephemeral fever virus, improves the content and yield of the virus antigen, and has a high automation degree; The synergistic effect of all the steps can jointly improve the quality and stability of the vaccine, and the technical problems that the yield of the bovine ephemeral fever virus produced by cell culture through a traditional spinner bottle or microcarrier process is low, the process is tedious, the difference between virus antigen batches is large, the vaccine efficacy is low, the vaccine validity period is short and the like are solved.

The present invention is directed to methods of evaluating whether an antigen or vaccine has degraded over time using liquid chromatography. The methods described herein also relate to using liquid chromatography to evaluate the relative potency of a given antigen or vaccine.

Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.